Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life
Although the use of prophylaxis regimens with prolonged half-life factors is now widespread in the world of hemophilia A, there is a lack of real-life evidence on the impact of these products on joint health, adherence, and quality of life of patients. Turoctocog alfa pegol is a glycoPEGylated reco...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2024-04-01
|
| Series: | Bleeding, Thrombosis and Vascular Biology |
| Subjects: | |
| Online Access: | https://www.btvb.org/btvb/article/view/104 |